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Background: In the absence of unified treatment protocol, we evaluated the manage-
ment and outcomes of submandibular gland cancers in an unselected patient series.
Methods: We included all patients with resected submandibular gland cancer treated
at the Helsinki University Hospital from 2000 to 2010 with a 5-year minimum
follow-up.
Results: Twenty-five patients with cancer represented 30% of submandibular gland
neoplasms, and most were adenoid cystic carcinomas (ACCs; 56%). At presentation,
3 patients showed clinical signs of probable malignancy. Of 22 neck dissection speci-
mens, 5 patients (20%) had metastases with an occult metastasis rate of 4%. Cancer
recurred in 11 patients (44%), of which 7 (28%) were only at a distant site. The 5-
year disease-specific survival (DSS) and overall survival (OS) rates were 76%, and
disease-free survival (DFS) was 68%.
Conclusion: Most tumors were ACCs differing from the histological pattern of
parotid gland cancers. Occult metastases were rare. The rarity of submandibular gland
cancer, its variable histological pattern, and varying biological behavior warrant
centralized management.
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1 | INTRODUCTION
Submandibular gland tumors are rare, accounting for 7%–
11% of salivary gland neoplasms,1,2 where 30%–54% are
malignant.1–4 The 2017 World Health Organization (WHO)
classification divides salivary gland carcinomas into 20 differ-
ent histological types, some of which are further divided into
subtypes.1 Thus, the diagnostics and treatment of salivary
gland carcinomas differ from other head and neck carcino-
mas, of which over 90% are squamous cell carcinomas
(SCCs). Mucoepidermoid carcinoma (MEC) and adenoid
cystic carcinoma (ACC) are among the most frequent malig-
nancies encountered in the major salivary glands.5 Treatment
recommendations for salivary gland carcinomas are usually
based on parotid gland tumors. Still, the biological behaviors
of parotid and submandibular gland tumors can vary.5
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The treatment of submandibular gland tumors remains
challenging because the exact nature of the lesion is often
unknown before or at the time of surgery. Inflammatory
lesions are common and generally easy to differentiate from
neoplasms using patient history, clinical examination, and
ultrasound. Sometimes, inflammatory diseases, such as scle-
rosing sialadenitis, can resemble a malignant tumor. In the
presence of neoplastic lesions, differentiating between benign
and malignant lesions is often difficult. Because the histol-
ogy of the tumor is seldom known preoperatively, the extent
of surgical treatment to the neck is especially difficult to
plan. We previously evaluated the treatment plans of all sub-
mandibular gland tumors at our institution during an 11-year
period, and identified the challenges in differentiating
between benign and malignant tumors.4 In our series, 30% of
submandibular gland tumors were malignant. We found fine-
needle aspiration cytology (FNAC) under ultrasound guid-
ance beneficial in treatment planning, while also considering
its well-known limitations. Inadequate preoperative planning
led to the need for additional surgeries when the histopatho-
logical examination revealed malignancy. Among all patients
with a neoplasm, regional metastases were encountered in
6% of cases, that is, in 20% of malignancies.
Given the above, it seems obvious that applying
generally accepted treatment guidelines could optimize the
management of submandibular gland tumors. In the present
study, we evaluate the treatment and outcome of submandib-
ular gland cancers.
2 | PATIENTS AND METHODS
We included all patients who had undergone surgery at our
institution for a malignant submandibular gland tumor
between January 1, 2000, and December 31, 2010. Patient
demographics, treatment, and follow-up data for 25 eligible
patients were reviewed after January 1, 2017. We collected
data on patient history, symptoms, clinical signs, imaging,
FNAC, surgery, histopathological examination, pathologic
TNM classification,6 oncologic treatment, and follow-up. No
other submandibular gland malignancies were diagnosed or
treated at other hospitals within our university hospital dis-
trict, which covers a population of 1.6 million people. The
research ethics committee at the Helsinki University Hospital
approved the study design and institutional research permis-
sion was granted.
We reevaluated and compared the histopathological
specimens and MRI scans with the original pathological and
imaging data. The criteria for malignancy, which is described
elsewhere, were used to reevaluate the MRI scans.7
All patients had a minimum follow-up of 5 years or until
death.
For statistical analyses, we used the IBM SPSS version
20.0 (SPSS, Chicago, IL). The 5-year overall survival (OS),
disease-specific survival (DSS), and disease-free survival
(DFS) figures were calculated using the Kaplan-Meier esti-
mate. The length of follow-up was calculated starting from
the last day of treatment through the end of follow-up or
death from any cause (OS) and disease-specific death (DSS).
The length of DFS was calculated starting from the last treat-
ment day through the detection of cancer recurrence at any
site or death.
3 | RESULTS
Our study population of 25 patients included 12 men (48%)
and 13 women (52%) with a mean age of 59.6 years (range
26-88 years). The tumor characteristics are provided in Table
1. Due to the variety of tumors and their treatment, patient
data are shown in Table 2.
The histological type did not change upon reevaluation in
any of the cases. The most common histological type was
ACC (14/25; 56%), followed by 6 other histological catego-
ries. Two tumors, both more than 2 cm in diameter, were




Salivary duct carcinoma 3 12
Acinic cell carcinoma 2 8
Carcinoma in pleomorphic adenoma 2 8
SCC 2 8
MEC 1 4
Sebaceous carcinoma 1 4
Pathological T classification














Abbreviations: ACC, adenoid cystic carcinoma; MEC, mucoepidermoid
carcinoma; SCC, squamous cell carcinoma.
aNeck dissection was not performed on 3 patients with clinically N0. These
patients are included in the figures.
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reclassified as in situ carcinomas (stage 0)—both were within
pleomorphic adenoma with an intact capsule. Both patients
with SCC were initially identified as having unknown primar-
ies, but the final histopathological examination of the neck dis-
section specimen revealed a tumor originating from the
submandibular gland without any another detectable primary
site.
The majority of the tumors were diagnosed at an early
stage: 16 (16/25; 64%) were stage 0 to II, and altogether
tumors in 20 patients (20/25; 80%) were classified as T in
situ, T1, or T2 tumors. Histopathological examination
revealed metastatic lymph nodes (pN1) in 5 patients (5/25;
20%). In addition, 20 patients (20/25; 80%) showed no neck
metastases, 17 of which were verified from neck dissection
specimens and 3 were clinically N0 (cN0) without recurrence
through follow-up.
3.1 | Symptoms and clinical signs
The most common finding was a symptomless mass, in
which palpation revealed only a single lump in 21 patients
(21/25; 84%). Obvious malignancy was suspected in 3 cases
(3/25; 12%): 1 patient had 2 palpable lumps, whereas 2
patients presented with a tumor growth (both SCCs) that
raised suspicion. No patients had neurological symptoms or
lingual, hypoglossal, or facial nerve functional deficits, and
21 patients (21/25; 84%) reported no pain. The average time
interval between appearance of the mass and attendance at
the clinic varied from an incidental finding to 10 years (<3
months, n5 7; 3-6 months, n5 5; about 1 year, n5 4; and
2-10 years, n5 9).
3.2 | Imaging
All patients underwent ultrasound and ultrasound-guided
FNAC. The ultrasounds showed (1) a solid tumor with regu-
lar borders (13/25; 52%); (2) irregular borders (4/25; 16%);
(3) a cystic-solid lesion (3/25; 12%); or (4) a highly vascular-
ized lesion with low echogenicity (2/25; 8%). All 3 patients
with obvious clinical findings for malignancy also showed
malignant signs upon ultrasound. Abnormal or enlarged
lymph nodes were reported in 6 patients, with pN1 in 3
patients (3/25; 12%).
The MRI scans were performed on 15 patients (15/25;
60%) and 2 patients (2/25; 8%) underwent CT scans. The
main indications included clinical signs of malignancy,
FNAC classes 0, III, IV, and V, and/or suspicion of
malignancy upon ultrasound. In 1 patient, the tumor was an
incidental finding upon CT.
The primary MRI reports identified 2 tumors as benign,
and 5 tumors as malignant, but provided no definitive state-
ment about the tumors in the remaining 8 patients. In the
neck, MRI showed suspicious lymph nodes in 5 patients, 4
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Reevaluation of the MRI scans was possible in 12 cases
showing signs of potential malignancy as follows: T2 hypo-
intensity in 6 patients (all after FNAC), irregular margins in
8 patients, extraglandular growth in 5 patients, and perineural
growth in 1 patient. Pathological lymph nodes were noted in
4 patients (these same 4 patients were also correctly diag-
nosed in the primary reports). At least 1 of the above-
mentioned signs was present in 11 of 12 reevaluated tumors,
and 10 tumors presented with at least 2 MRI signs of poten-
tial malignancy.
3.3 | Primary surgery
All 25 patients underwent surgery with a curative intent.
Among the 11 patients (11/25; 44%) who only had the gland
removed primarily without neck dissection, 8 did not present
with any indications of possible malignancy, whereas 3 had
class III upon FNAC. Furthermore, 14 patients (14/25; 56%)
also had neck dissection primarily (Table 2). Frozen section
analysis was used for 8 patients (8/25; 32%), and malignancy
was indicated in all but 1.
3.4 | Additional surgery and neck metastases
The tumor board recommended additional surgery for 10
patients (10/25; 40%) due to inadequate margins or the type
of histology or both. Eight of these patients previously under-
went removal of the gland only without neck dissection. The
specimens from the subsequent surgeries revealed remaining
carcinoma in 5 patients (5/10; 50%) at the primary site, and
pN1 in only 1 patient with salivary duct carcinoma.
Including the additional surgeries in our analysis, we
found that 22 patients (22/25; 88%) ultimately underwent at
least levels I to III neck dissection. The exact levels of the
metastatic lymph nodes remained unknown because the lev-
els were unmarked in the dissection specimens. All 5 patients
(5/25; 20%) with pN1 had at least 2 ipsilateral metastases
(pN2b). Only 1 patient (with SCC) had occult metastases,
yielding an occult metastatic rate of 4% (1/25). Among
ACCs, only 1 patient (1/14; 7%) had pN1.
3.5 | Oncologic treatment for primary
tumors
Postoperative radiotherapy (RT) was given to 15 patients (15/
25; 60%) with an average dose of 60 Gy (range 50-70 Gy).
Among these 15 patients, 3 had salivary duct carcinomas and
received cisplatin 40mg/m2 once weekly as concomitant
chemotherapy together with RT (chemoradiotherapy [CRT]).
The RT was administered using a linear accelerator with 6
MV photons. A thermoplastic head and neck mask was used
for immobilization. Five patients were treated using conven-
tional 3D RT, and 10 patients received intensity-modulated
radiotherapy. The clinical target volume encompassed the sur-
gical bed of the submandibular gland with wide margins, and
14 patients also received a total dose of up to 50 Gy at the
ipsilateral neck. All patients were treated with conventional 2
Gy daily fractions administered 5 times a week.
3.6 | Recurrent tumors and follow-up
No patients were lost to follow-up, and the median follow-up
time for patients alive at the end of the follow-up period was
9.0 years (range 5.0-16.0 years).
Locoregional recurrences occurred in 4 patients (4/25;
16%) within a median of 0.6 years (range 0.1-2.2 years).
Three of these patients received further treatment with a
curative intent and all subsequently died with disease. Dis-
tant metastasis in the lungs or liver without locoregional
recurrence was encountered in 7 patients (7/25; 28%) within
a median of 4.6 years (range 0.1-8.8 years).
Of the 14 patients with ACC, 6 experienced recurrence
during follow-up. Two tumors recurred locoregionally and 4
patients developed distant metastasis in the lungs or liver
within a median of 4.7 years (range 0.5-8.8 years).
The 5-year DSS and OS rates were both 76%, and the
DFS rate was 68%.
4 | DISCUSSION
This study included all malignant submandibular gland
tumors diagnosed and treated during an 11-year period
within a catchment area of 1.6 million people in Southern
Finland,8 all treated at a single university hospital. We previ-
ously reported that malignant submandibular gland tumors
represented 30% of all submandibular gland neoplasms in
our study,4 somewhat lower than typically reported,2,3 yet in
line with a more recent study.9 Comparable with other
reports,9–12 most malignant tumors in our study were ACCs
(56%). Reflecting our results, Han et al10 found that salivary
duct carcinoma (22%) and carcinoma ex pleomorphic ade-
noma (17%) were the next most common histological types
encountered in submandibular gland malignancies. In addi-
tion to ACC, MEC and acinic cell carcinoma are among the
most common histological types in parotid gland cancers.13
Although 36% of the patients in the present study sought
medical attention more than a year after the onset of symp-
toms—which is not uncommon14—most tumors (64%) were
still diagnosed at an early stage (stages 0-II), unlike the find-
ings reported by others.10,11 This may partially explain the
somewhat surprising finding that only 3 patients had symp-
toms or clinical signs arousing suspicion of malignancy, and
the most common finding of a symptomless mass only. This
is in line with other studies, which showed that, in patients
with ACC, a mass is the most common symptom, occurring
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in 77%14 to 98%15 of cases. Pain was reported by 48% of
patients with ACC in a study by Nascimento et al,15 whereas
another study found that only 7% of patients reported experi-
encing pain.16
An MRI or CT was used in 68% of the present patients.
In our limited sample, MRI provided a somewhat higher
accuracy estimating the cervical lymph node status compared
to ultrasound. Particularly noteworthy, unlike ultrasound, at
our institution, dedicated head and neck radiologists perform
most MRI studies, possibly contributing to these results. An
unblinded second review of an MRI revealed some signs of
potential malignancy in all but 1 of the 12 reevaluated scans.
None of the available scans included modern techniques,
such as diffusion-weighted imaging, dynamic contrast-
enhancement, or proton magnetic resonance spectroscopy,
possibly further increasing the diagnostic accuracy of differ-
entiating benign from malignant tumors.17–20 In our recent
publication, which also included benign submandibular gland
tumors, we discussed the role of ultrasound and MRI in the
diagnosis of submandibular gland lesions.4
Because the histology is seldom known at the time of
surgery, treatment of the neck remains a challenge, especially
in cases with cN0. The diagnosis of ACC generally does not
call for elective neck dissection (END),10,14 in contrast to sal-
ivary duct carcinoma.21–23 Still, some recommend END for
all patients with salivary gland carcinoma.24 The rate of neck
metastases in samples, including all submandibular gland
cancers, varies. For instance, some studies report high figures
of up to 45%10 and 50%,24 whereas we found a rate of 20%.
Furthermore, our cohort included many patients at an early
stage of disease. The rate of occult metastases also varies
across studies. In addition to the different tumor stages and
histologies reported between studies, the rate of occult metas-
tases obviously depends on the diagnostic imaging methods.
A study by Han et al10 reported an occult metastatic rate of
20% among patients with submandibular gland cancer. Most
specialists recommend END for all high-grade tumors,5,10,25
excluding ACC,10 which is in line with our study because
ACCs carried a metastatic rate of only 7%. Hirvonen et al16
found that 12% of patients with major salivary gland ACC
presented with pN1. In their study, the occult metastatic rate
was only 4%, despite that the study consisted of an older
patient population treated when modern imaging methods
were unavailable.16 Similarly, Cohen et al14 reported no
occult metastases in submandibular gland ACC. By contrast,
among all salivary gland carcinomas, Yoo et al5 reported
occult metastases in 19% of ACCs.
Including routine neck dissection in all cases would
result in overtreatment, because most submandibular gland
tumors are benign, ACC is the most common malignant
tumor, and occult metastases are uncommon. Still, including
additional surgeries, most of our patients with malignancy
underwent level IB or more extensive neck dissection, a
commonly reported tendency in retrospective studies of
ACC.14,16 We suggest that eventual neck dissection and its
extent should be planned based on the cytological and radio-
logical findings. Whenever malignancy is suspected (class III
cytology or other criteria), we recommend extending surgery,
at least to level IB, or to levels I to III depending on the case.
Frozen section analysis can also prove useful in planning the
extent of surgery, especially on the neck.4,24,26
Among 10 patients (40%) in our cohort, additional sur-
gery revealed remaining malignant tissue in 5 patients, but
pN1was found in only 1 patient. Some argue that the surgi-
cal field at this site may be limited due to the close proximity
to vital structures, which can lead to positive surgical mar-
gins.14 Thus, wider surgical margins may be warranted.
Because positive surgical margins are often encountered in
high-grade tumors,22,23,27,28 additional surgery would prob-
ably fail to improve the margins but could compromise vital
structures. Furthermore, for high-grade tumors, such as
ACC, postoperative RT is usually scheduled in the presence
of additional adverse factors, such as T3 to T4 tumors,
incomplete resection, and bone or perineural invasion.25,29
Postoperative RT increases local control of ACC, even in the
presence of a residual tumor, although RT may also merely
delay recurrence, which often occurs late during follow-up.28
In this study, postoperative RT was administered for 60% of
patients, of whom 87% were thought to have a high-grade
tumor. The addition of RT was often warranted despite addi-
tional surgery.
Chemotherapy is mainly restricted to locally recurrent or
distant metastatic disease,30,31 although CRT may not
improve survival.32–34 Still, contradictory results have been
reported.35,36 Thus, postoperative CRT, usually including
cisplatin, has also been used in the treatment of high-risk sal-
ivary gland carcinomas, of which the ongoing clinical trial
Radiation Therapy Oncology Group 1008 should provide
new insight.37 Postoperative chemotherapy is recommended
for salivary duct carcinoma, which carries a high risk for dis-
tant metastasis, even without a clear distant control or sur-
vival benefit.22 Additionally, among older patients, adjuvant
CRT carries more toxicity and mortality than RT alone.38
Gao et al39 reported that neither surgery nor oncologic treat-
ment significantly impacted survival among patients with
ACC with distant metastasis.
Androgen deprivation therapy40–43 and targeted human
epidermal growth factor receptor 2 therapy40,44 for salivary
duct carcinoma may prove beneficial. Anti-epidermal growth
factor receptor therapy, especially in ACC, has been shown
to stabilize disease progression in patients with relapse or
metastases.45 Targeted therapy was utilized in 3 recurrent
tumors in our cohort.
In our cohort, 44% of patients experienced a recurrence
during follow-up, and 28% incurred distant metastasis with-
out recurrence at the locoregional site. Other researchers
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reported slightly higher figures for distant metastasis; Roh
et al12 found that 31% of patients (19/62) experienced recur-
rence within a mean follow-up period of 64 months. A study
by Han et al10 reported a distant metastasis rate of 36% (23/
64) within a mean follow-up time of 48 months—most fre-
quently in the lungs, liver, or brain—when all submandibular
gland cancers were considered, but only 12% in ACCs. By
contrast, Hirvonen et al,16 at our institution, reported that
50% of patients treated for major salivary gland ACC devel-
oped distant metastases, typically within 10 years. The solid
subtype of ACC carries a higher risk for distant metastasis
and a worse survival.16,39,46 In our series, however, distant
metastasis occurred in patients presenting with tumors of
mainly the cribriform subtype. Due to the limited number of
cases in our series, no definitive conclusions can be drawn.
Furthermore, 32% of the patients in our series died with
disease during follow-up. Comparatively, Han et al10
reported a 44% mortality rate in a series of 64 patients with
submandibular gland cancer during a 5-year follow-up. The
difference between these rates may result from the fact that,
in the series by Han et al,10 the rate of ACCs was lower
(27%). Additionally, most patients presented with more
advanced tumors because 72% were diagnosed as stage III or
IV. However, in our series, 4 of the 5 patients with neck
metastases died of disease and the 1 patient still living at the
end of the follow-up had distant metastasis. Our 5-year DFS
and OS rates are comparable to those reported by Cohen
et al14 who included only submandibular gland ACCs. How-
ever, our survival rates are higher than those reported in
series that included fewer ACCs.10,11 Because ACCs often
recur years after treatment, a longer follow-up, such as> 10
years for all patients, would most likely lower the survival
rates.
Some studies indicate that the prognosis of patients with
submandibular gland cancer is worse than patients with
parotid gland cancer.5,47,48 Nobis et al24 found no difference
between parotid gland and submandibular gland tumors in
their ability to metastasize to the neck; Terhaard et al29
reported an opposite finding. Furthermore, a study by
Armstrong et al49 noted a higher incidence of occult metasta-
ses in submandibular gland tumors (21%) than in parotid
gland tumors (9%). Additionally, the occurrence of distant
metastasis in submandibular gland tumors (37%-42%) seems
higher than in parotid gland tumors (17%-29%).39,47
5 | CONCLUSIONS
Clinical examination, preoperative imaging, and cytology
may reveal no signs of malignancy or indicate benign find-
ings in submandibular gland tumors that turn out malignant.
Additionally, the lengthy time interval before the patient
seeks medical attention may not raise the suspicion of
malignancy. Utilizing FNAC, MRI, frozen section, and
including level IB in the surgical field for inconclusive cases
may assist in achieving an optimal extent of surgery. Routine
extensive END does not seem advisable because occult
metastases are rare and most malignant tumors are ACCs. In
general, however, the higher propensity of submandibular
gland tumors to metastasize to the neck compared with
parotid gland tumors requires careful consideration. Due to
the heterogeneity of submandibular gland malignancies,
including the higher rate of distant metastasis, their evalua-
tion and treatment must be individually tailored and central-
ized at experienced head and neck centers.
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